Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Taps Roche Antibody, Green Lights Testing Kits For Coronavirus Arsenal

Executive Summary

Kicking a rapid response mechanism into full gear, China approves Roche’s Actemra as a new treatment for coronavirus along with a flurry of testing kits.

You may also be interested in...



Spanish Biotechs Join Battle Against COVID-19

Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.

India Coronavirus Actions: Stock Checks, Kaletra Gx Readiness And Bulk Drugs

A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.

Sanofi To Test Arthritis Drug Kevzara For Coronavirus

The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141781

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel